- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Eye on Pharma: Biocad Forges Ahead With Biosimilar Infliximab
Biocad, a Russia-based drug manufacturer, received approval for an infliximab biosimilar (referencing Remicade) from Russia’s Federal Drug Control Service last month. The company anticipates expanding to other markets as soon as later this year, or early 2019.
Biocad, a Russia-based drug manufacturer, received approval for an infliximab biosimilar (referencing Remicade) from Russia’s Federal Drug Control Service last month. The company anticipates expanding to other markets as soon as later this year, or early 2019.
In order to receive regulatory approval, Biocad completed international clinical studies of the infliximab biosimilar in direct comparison with the reference product. The infliximab biosimilar was investigated in treating indications of its reference, specifically ankylosing spondylitis and rheumatoid arthritis (RA).
The studies found that the therapeutic effects of the biosimilar were shown to be equivalent to the reference. In addition, the safety profiles of the 2 drugs were also similar in the long-term.
Biocad reportedly believes that India will be the first country to receive shipments of the biosimilar, where the infliximab market is valued at around $50 million for 2018.
Infliximab is the fourth monoclonal antibody biosimilar for which Biocad has gained regulatory approval. Past approvals include biosimilars of bevacizumab, trastuzumab, and rituximab. The drug maker won its patent dispute over rituximab with the reference manufacturer, Roche, last October.
Around the same time this legal win was announced, Biocad revealed intentions to enter the European market with oncological and autoimmune therapies. The company has both innovative and biosimilar products currently for sale in Europe, spanning treatments for melanoma; breast, stomach, kidney, and lung cancer; RA; psoriasis; and multiple sclerosis.
“As for the European Union countries, where the approval of biological product goes under centralized procedure through the European Medicines Agency, taking into account the need for local clinical trials, we expect to get marketing authorization for biological products in 2021,” said Dmitry Morozov, general director of Biocad.
According to a press release, the company estimates that, in 2021, its generics of oncology drugs docetaxel, paclitaxel, pemetrexed, and irinotecan will also enter the European market.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.
